公开(公告)号：EP1615613A2

公开(公告)日：2006-01-18

申请号：EP04750236.4

申请日：2004-04-16

申请人： Enanta Pharmaceuticals, Inc.

发明人： NAKAJIMA, Suanne ,  SUN, Ying ,  TANG, Datong ,  XU, Gouyou ,  PORTER, Brian ,  OR, Yat, Sun ,  WANG, Zhe ,  MIAO, Zhenwei

IPC分类号： A61K6/00

CPC分类号： C07K5/0804 ,  C07D487/04

摘要： The present invention relates to compounds of Formula (I) or (II), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: formula (I), formula (II): which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：EP1885737A2

公开(公告)日：2008-02-13

申请号：EP06769971.0

申请日：2006-05-02

申请人： Enanta Pharmaceuticals, Inc.

发明人： WANG, Guoqiang ,  PHAN, Ly, Tam ,  OR, Yat, Sun ,  QIU, Yao-ling ,  NIU, Deqiang ,  PENG, Yulin ,  BUSUYEK, Marina ,  WANG, Yanchun ,  NAKAJIMA, Suanne

IPC分类号： C07H17/08 ,  A01N43/22 ,  A61K31/7042

CPC分类号： C07H17/08

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof (see formula I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.

公开(公告)号：EP1615613B1

公开(公告)日：2009-11-04

申请号：EP04750236.4

申请日：2004-04-16

申请人： Enanta Pharmaceuticals, Inc.

发明人： NAKAJIMA, Suanne ,  SUN, Ying ,  TANG, Datong ,  XU, Gouyou ,  PORTER, Brian ,  OR, Yat, Sun ,  WANG, Zhe ,  MIAO, Zhenwei

IPC分类号： C07D487/04 ,  A61K31/38 ,  A61K31/395 ,  A61P31/12 ,  C07D401/12 ,  C07D409/14 ,  C07K5/08

CPC分类号： C07K5/0804 ,  C07D487/04

摘要： The present invention relates to compounds of Formula (I) or (II), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: formula (I), formula (II): which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：EP1590442A3

公开(公告)日：2005-12-21

申请号：EP04709020.4

申请日：2004-02-06

申请人： Enanta Pharmaceuticals, Inc.

发明人： MIAO, Zenwei ,  SUN, Ying ,  WU, Frank ,  NAKAJIMA, Suanne ,  XU, Guoyou ,  OR, Yat, Sun ,  WANG, Zhe

IPC分类号： C12N1/00

公开(公告)号：EP1590442A2

公开(公告)日：2005-11-02

申请号：EP04709020.4

申请日：2004-02-06

申请人： Enanta Pharmaceuticals, Inc.

发明人： MIAO, Zenwei ,  SUN, Ying ,  WU, Frank ,  NAKAJIMA, Suanne ,  XU, Guoyou ,  OR, Yat, Sun ,  WANG, Zhe

IPC分类号： C12N1/00

CPC分类号： C07D487/04 ,  A61K38/00 ,  C07D513/04 ,  C07K5/02 ,  C07K5/0806

摘要： The present invention relates to compounds of Formula (I, II or III), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: (I), (II), (III), wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.